Citi has increased its price target for GSK PLC (LSE:GSK, NYSE:GSK) to £22.50 whilst maintaining a neutral rating on the pharmaceutical group following a notable rally in the shares driven
All posts tagged in drug development pipeline
2Articles
AstraZeneca, the FTSE 100 pharmaceutical giant, has reaffirmed its full-year forecasts despite posting mixed first-quarter results and grappling with potential headwinds in major markets. The company reported a 10 per
